MedTrace Logo

Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

NCT02870569 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2019-03-01

No results posted yet for this study

Summary

Donafenib for advanced 131I-refractory/resistant differentiated thyroid cancer(DTC).

Conditions

  • Differentiated Thyroid Cancer

Interventions

DRUG

Donafenib 200mg

Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the lower dose one.

DRUG

Donafenib 300mg

Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the higher dose one.

Sponsors & Collaborators

  • Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2018-07-02
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02870569 on ClinicalTrials.gov